BIO-B
Bio-Rad Laboratories Inc
365.10$
+0.0%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 46.9% | 46.3% | 46.6% | 44.3% | 45.2% | 48.8% | 47.7% | 47.0% | 47.4% | 50.2% | 47.7% | 46.9% | 48.1% | |
| 53.1% | 53.7% | 53.4% | 55.6% | 54.8% | 51.2% | 52.3% | 53.0% | 52.6% | 49.8% | 52.3% | 53.1% | 51.9% | |
| 6.9% | 9.1% | 10.5% | 9.3% | 14.0% | 11.9% | 12.6% | 9.3% | 10.9% | 9.5% | 10.6% | 9.4% | 10.1% | |
| 31.8% | 30.4% | 35.2% | 30.5% | 30.8% | 30.6% | 35.7% | 31.9% | 31.7% | 31.9% | 35.9% | 32.6% | 32.9% | |
| 38.7% | 39.4% | 44.9% | 39.7% | 44.9% | 42.5% | 48.2% | 41.2% | 42.6% | 40.7% | 46.5% | 42.0% | 42.8% | |
| 14.4% | 14.4% | 8.5% | 15.9% | 9.9% | 8.7% | 4.0% | 11.8% | 10.2% | 8.9% | 5.8% | 11.2% | 9.1% | |
| 2.0% | 1.8% | 2.0% | 1.9% | 1.9% | 1.8% | 2.0% | 1.9% | 1.9% | 1.7% | 2.1% | 1.9% | 1.9% | |
| 21.7% | 62.9% | 80.4% | -436.4% | 132.6% | -136.2% | 14.2% | 63.5% | -66.0% | 134.0% | -116.5% | 83.3% | 13.5% | |
| 4.9% | 11.6% | 17.5% | -97.2% | 32.1% | -28.9% | 3.3% | 14.8% | -13.7% | 30.2% | -27.5% | 26.2% | 4.9% | |
| 16.8% | 51.3% | 62.9% | -339.2% | 100.5% | -107.2% | 10.9% | 48.8% | -52.4% | 103.9% | -89.0% | 57.1% | 8.6% | |
| 31.3% | 72.5% | 90.2% | -427.2% | 142.0% | -127.0% | 22.8% | 73.2% | -55.8% | 143.3% | -107.5% | 83.3% | 20.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.